Cargando…
Immunotherapy-related adverse events in real-world patients with advanced non-small cell lung cancer on chemoimmunotherapy: a Spinnaker study sub-analysis
BACKGROUND: The Spinnaker study evaluated survival outcomes and prognostic factors in patients with advanced non-small-cell lung cancer receiving first-line chemoimmunotherapy in the real world. This sub-analysis assessed the immunotherapy-related adverse effects (irAEs) seen in this cohort, their i...
Autores principales: | , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10265987/ https://www.ncbi.nlm.nih.gov/pubmed/37324003 http://dx.doi.org/10.3389/fonc.2023.1163768 |
_version_ | 1785058648224956416 |
---|---|
author | Anpalakhan, Shobana Huddar, Prerana Behrouzi, Roya Signori, Alessio Cave, Judith Comins, Charles Cortellini, Alessio Addeo, Alfredo Escriu, Carles McKenzie, Hayley Barone, Gloria Murray, Lisa Pinato, David J. Ottensmeier, Christian Campos, Sara Muthuramalingam, Sethupathi Chan, Samuel Gomes, Fabio Banna, Giuseppe L. |
author_facet | Anpalakhan, Shobana Huddar, Prerana Behrouzi, Roya Signori, Alessio Cave, Judith Comins, Charles Cortellini, Alessio Addeo, Alfredo Escriu, Carles McKenzie, Hayley Barone, Gloria Murray, Lisa Pinato, David J. Ottensmeier, Christian Campos, Sara Muthuramalingam, Sethupathi Chan, Samuel Gomes, Fabio Banna, Giuseppe L. |
author_sort | Anpalakhan, Shobana |
collection | PubMed |
description | BACKGROUND: The Spinnaker study evaluated survival outcomes and prognostic factors in patients with advanced non-small-cell lung cancer receiving first-line chemoimmunotherapy in the real world. This sub-analysis assessed the immunotherapy-related adverse effects (irAEs) seen in this cohort, their impact on overall survival (OS) and progression-free survival (PFS), and related clinical factors. METHODS: The Spinnaker study was a retrospective multicentre observational cohort study of patients treated with first-line pembrolizumab plus platinum-based chemotherapy in six United Kingdom and one Swiss oncology centres. Data were collected on patient characteristics, survival outcomes, frequency and severity of irAEs, and peripheral immune-inflammatory blood markers, including the neutrophil-to-lymphocyte ratio (NLR) and systemic immune-inflammation index (SII). RESULTS: A total of 308 patients were included; 132 (43%) experienced any grade irAE, 100 (32%) Grade 1–2, and 49 (16%) Grade 3–4 irAEs. The median OS in patients with any grade irAES was significantly longer (17.5 months [95% CI, 13.4–21.6 months]) than those without (10.1 months [95% CI, 8.3–12.0 months]) (p<0.001), either if Grade 1–2 (p=0.003) or Grade 3–4 irAEs (p=0.042). The median PFS in patients with any grade irAEs was significantly longer (10.1 months [95% CI, 9.0–11.2 months]) than those without (6.1 months [95% CI, 5.2–7.1 months]) (p<0.001), either if Grade 1–2 (p=0.011) or Grade 3–4 irAEs (p=0.036). A higher rate of irAEs of any grade and specifically Grade 1–2 irAEs correlated with NLR <4 (p=0.013 and p=0.018), SII <1,440 (p=0.029 ad p=0.039), response to treatment (p=0.001 and p=0.034), a higher rate of treatment discontinuation (p<0.00001 and p=0.041), and the NHS-Lung prognostic classes (p=0.002 and p=0.008). CONCLUSIONS: These results confirm survival outcome benefits in patients with irAEs and suggest a higher likelihood of Grade 1–2 irAEs in patients with lower NLR or SII values or according to the NHS-Lung score. |
format | Online Article Text |
id | pubmed-10265987 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-102659872023-06-15 Immunotherapy-related adverse events in real-world patients with advanced non-small cell lung cancer on chemoimmunotherapy: a Spinnaker study sub-analysis Anpalakhan, Shobana Huddar, Prerana Behrouzi, Roya Signori, Alessio Cave, Judith Comins, Charles Cortellini, Alessio Addeo, Alfredo Escriu, Carles McKenzie, Hayley Barone, Gloria Murray, Lisa Pinato, David J. Ottensmeier, Christian Campos, Sara Muthuramalingam, Sethupathi Chan, Samuel Gomes, Fabio Banna, Giuseppe L. Front Oncol Oncology BACKGROUND: The Spinnaker study evaluated survival outcomes and prognostic factors in patients with advanced non-small-cell lung cancer receiving first-line chemoimmunotherapy in the real world. This sub-analysis assessed the immunotherapy-related adverse effects (irAEs) seen in this cohort, their impact on overall survival (OS) and progression-free survival (PFS), and related clinical factors. METHODS: The Spinnaker study was a retrospective multicentre observational cohort study of patients treated with first-line pembrolizumab plus platinum-based chemotherapy in six United Kingdom and one Swiss oncology centres. Data were collected on patient characteristics, survival outcomes, frequency and severity of irAEs, and peripheral immune-inflammatory blood markers, including the neutrophil-to-lymphocyte ratio (NLR) and systemic immune-inflammation index (SII). RESULTS: A total of 308 patients were included; 132 (43%) experienced any grade irAE, 100 (32%) Grade 1–2, and 49 (16%) Grade 3–4 irAEs. The median OS in patients with any grade irAES was significantly longer (17.5 months [95% CI, 13.4–21.6 months]) than those without (10.1 months [95% CI, 8.3–12.0 months]) (p<0.001), either if Grade 1–2 (p=0.003) or Grade 3–4 irAEs (p=0.042). The median PFS in patients with any grade irAEs was significantly longer (10.1 months [95% CI, 9.0–11.2 months]) than those without (6.1 months [95% CI, 5.2–7.1 months]) (p<0.001), either if Grade 1–2 (p=0.011) or Grade 3–4 irAEs (p=0.036). A higher rate of irAEs of any grade and specifically Grade 1–2 irAEs correlated with NLR <4 (p=0.013 and p=0.018), SII <1,440 (p=0.029 ad p=0.039), response to treatment (p=0.001 and p=0.034), a higher rate of treatment discontinuation (p<0.00001 and p=0.041), and the NHS-Lung prognostic classes (p=0.002 and p=0.008). CONCLUSIONS: These results confirm survival outcome benefits in patients with irAEs and suggest a higher likelihood of Grade 1–2 irAEs in patients with lower NLR or SII values or according to the NHS-Lung score. Frontiers Media S.A. 2023-05-31 /pmc/articles/PMC10265987/ /pubmed/37324003 http://dx.doi.org/10.3389/fonc.2023.1163768 Text en Copyright © 2023 Anpalakhan, Huddar, Behrouzi, Signori, Cave, Comins, Cortellini, Addeo, Escriu, McKenzie, Barone, Murray, Pinato, Ottensmeier, Campos, Muthuramalingam, Chan, Gomes and Banna https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Oncology Anpalakhan, Shobana Huddar, Prerana Behrouzi, Roya Signori, Alessio Cave, Judith Comins, Charles Cortellini, Alessio Addeo, Alfredo Escriu, Carles McKenzie, Hayley Barone, Gloria Murray, Lisa Pinato, David J. Ottensmeier, Christian Campos, Sara Muthuramalingam, Sethupathi Chan, Samuel Gomes, Fabio Banna, Giuseppe L. Immunotherapy-related adverse events in real-world patients with advanced non-small cell lung cancer on chemoimmunotherapy: a Spinnaker study sub-analysis |
title | Immunotherapy-related adverse events in real-world patients with advanced non-small cell lung cancer on chemoimmunotherapy: a Spinnaker study sub-analysis |
title_full | Immunotherapy-related adverse events in real-world patients with advanced non-small cell lung cancer on chemoimmunotherapy: a Spinnaker study sub-analysis |
title_fullStr | Immunotherapy-related adverse events in real-world patients with advanced non-small cell lung cancer on chemoimmunotherapy: a Spinnaker study sub-analysis |
title_full_unstemmed | Immunotherapy-related adverse events in real-world patients with advanced non-small cell lung cancer on chemoimmunotherapy: a Spinnaker study sub-analysis |
title_short | Immunotherapy-related adverse events in real-world patients with advanced non-small cell lung cancer on chemoimmunotherapy: a Spinnaker study sub-analysis |
title_sort | immunotherapy-related adverse events in real-world patients with advanced non-small cell lung cancer on chemoimmunotherapy: a spinnaker study sub-analysis |
topic | Oncology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10265987/ https://www.ncbi.nlm.nih.gov/pubmed/37324003 http://dx.doi.org/10.3389/fonc.2023.1163768 |
work_keys_str_mv | AT anpalakhanshobana immunotherapyrelatedadverseeventsinrealworldpatientswithadvancednonsmallcelllungcanceronchemoimmunotherapyaspinnakerstudysubanalysis AT huddarprerana immunotherapyrelatedadverseeventsinrealworldpatientswithadvancednonsmallcelllungcanceronchemoimmunotherapyaspinnakerstudysubanalysis AT behrouziroya immunotherapyrelatedadverseeventsinrealworldpatientswithadvancednonsmallcelllungcanceronchemoimmunotherapyaspinnakerstudysubanalysis AT signorialessio immunotherapyrelatedadverseeventsinrealworldpatientswithadvancednonsmallcelllungcanceronchemoimmunotherapyaspinnakerstudysubanalysis AT cavejudith immunotherapyrelatedadverseeventsinrealworldpatientswithadvancednonsmallcelllungcanceronchemoimmunotherapyaspinnakerstudysubanalysis AT cominscharles immunotherapyrelatedadverseeventsinrealworldpatientswithadvancednonsmallcelllungcanceronchemoimmunotherapyaspinnakerstudysubanalysis AT cortellinialessio immunotherapyrelatedadverseeventsinrealworldpatientswithadvancednonsmallcelllungcanceronchemoimmunotherapyaspinnakerstudysubanalysis AT addeoalfredo immunotherapyrelatedadverseeventsinrealworldpatientswithadvancednonsmallcelllungcanceronchemoimmunotherapyaspinnakerstudysubanalysis AT escriucarles immunotherapyrelatedadverseeventsinrealworldpatientswithadvancednonsmallcelllungcanceronchemoimmunotherapyaspinnakerstudysubanalysis AT mckenziehayley immunotherapyrelatedadverseeventsinrealworldpatientswithadvancednonsmallcelllungcanceronchemoimmunotherapyaspinnakerstudysubanalysis AT baronegloria immunotherapyrelatedadverseeventsinrealworldpatientswithadvancednonsmallcelllungcanceronchemoimmunotherapyaspinnakerstudysubanalysis AT murraylisa immunotherapyrelatedadverseeventsinrealworldpatientswithadvancednonsmallcelllungcanceronchemoimmunotherapyaspinnakerstudysubanalysis AT pinatodavidj immunotherapyrelatedadverseeventsinrealworldpatientswithadvancednonsmallcelllungcanceronchemoimmunotherapyaspinnakerstudysubanalysis AT ottensmeierchristian immunotherapyrelatedadverseeventsinrealworldpatientswithadvancednonsmallcelllungcanceronchemoimmunotherapyaspinnakerstudysubanalysis AT campossara immunotherapyrelatedadverseeventsinrealworldpatientswithadvancednonsmallcelllungcanceronchemoimmunotherapyaspinnakerstudysubanalysis AT muthuramalingamsethupathi immunotherapyrelatedadverseeventsinrealworldpatientswithadvancednonsmallcelllungcanceronchemoimmunotherapyaspinnakerstudysubanalysis AT chansamuel immunotherapyrelatedadverseeventsinrealworldpatientswithadvancednonsmallcelllungcanceronchemoimmunotherapyaspinnakerstudysubanalysis AT gomesfabio immunotherapyrelatedadverseeventsinrealworldpatientswithadvancednonsmallcelllungcanceronchemoimmunotherapyaspinnakerstudysubanalysis AT bannagiuseppel immunotherapyrelatedadverseeventsinrealworldpatientswithadvancednonsmallcelllungcanceronchemoimmunotherapyaspinnakerstudysubanalysis |